MSc Biotherapeutics and Business

Core Modules Stage 1
 

• Professional Career Development

  BIOC40180
   

• Business Strategy

  BMGT45430
   

• The Business of Biotechnology and Science

  BMOL40120
   

• Feasibility and Business Plan

  BMOL40130
   

• Teams in Biotech Enterprise

  BMOL40380
   

• Corporate Finance (BB)

  FIN41440
   

• Marketing Management MSc Bio&B

  MKT42310
   

• Biotherapeutic Pipeline I

  PHAR40200
   

• Biotherapeutic Pipeline II

  PHAR40210
   

• Systems Biology in Drug Dev

  PHAR40220
   

• Biotherapeutics Case Study

  PHAR40350

Optional Modules Stage 1
 

• Biomedical Diagnostics&Devices

  BIOC40250
   

• Biological Imaging

  BMOL40180
   

• Multicellular Systems

  BMOL40190
   

• HCS Microscopy

  CELB40160
   

• Recombinant DNA Technology

  MICR40010
   

• Emerging Issues in Biotechnology

  MICR40100
   

• Regulatory Affairs in Science

  PHAR40240

Candidates must have obtained at least an upper Second Class Honours (2:1) Grade or equivalent in an honours BSc in Biotechnology, Biochemistry, Microbiology, Genetics, Neuroscience, Physiology, Pharmacology, Medicinal Chemistry or an equivalent qualification.

If English is not your native language, unless you have done your primary degree through English in an English speaking country, an English language qualification is required for all programmes. English Language qualifications include a minimum score of 550 (213 computer based) for Test of English as a Foreign Language (TOEFL), or 6.5 (with a score of 6 obtained in each category) for International English Language Testing System (IELTS). 

Non-EU fees for academic year 2022/23 are:

€ 26,400

This advanced graduate degree in Biotherapeutics and Business has been developed in consultation with employers and therefore will be recognised and valued by them. A key feature is the opportunity to carry out a business development plan which will allow graduates to develop connections with prospective employers, thereby enhancing chances of employment on graduation.

Prospective employers include: Abbott; Allergan; Amgen; Baxter Healthcare; Eli Lilly and Co.; Dignity Sciences; Glaxo SmithKline; Icon Clinical Research; ImmunoGen Inc.; Janssen Pharmaceutical Ltd.; Johnson & Johnson Ltd.; Merck Sharp & Dohme; Quintiles; Quest International; Sandoz; Seroba Kernel.